Sorrento Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 949
- Market Cap
- -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT03682744
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Roger Williams Medical Center, Providence, Rhode Island, United States
Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT03542838
- Locations
- 🇺🇸
Snibbe Orthopedics, Los Angeles, California, United States
🇺🇸University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03464916
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Minnesota, Rochester, Minnesota, United States
🇺🇸Icahn School of Medicine, New York, New York, United States
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
- Conditions
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03229798
- Locations
- 🇺🇸
Carolina Phase 1 Research, Raleigh, North Carolina, United States
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03226574
- Locations
- 🇺🇸
University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Hermann Drive Surgical Hospital, Houston, Texas, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT02064829
- Locations
- 🇺🇦
Sorrento investigational site, Vinnytsya, Ukraine